Shunsuke Tamaki, Yohei Sotomi, Yoshiyuki Nagai, Ryu Shutta, Daisaku Masuda, Nobuhiko Makino, Shizuya Yamashita, Masahiro Seo, Takahisa Yamada, Akito Nakagawa, Yoshio Yasumura, Yusuke Nakagawa, Masamichi Yano, Takaharu Hayashi, Shungo Hikoso, Daisaku Nakatani, Tomohito Ohtani, Yasushi Sakata
AIMS: Interleukin-16 (IL-16) has been reported to mediate left ventricular myocardial fibrosis and stiffening in patients with heart failure with preserved ejection fraction (HFpEF). We sought to elucidate whether IL-16 has a distinct impact on pathophysiology and prognosis across different subphenotypes of acute HFpEF. METHODS AND RESULTS: We analysed 211 patients enrolled in a prospective multicentre registry of acute decompensated HFpEF for whom serum IL-16 levels after stabilization were available (53% female, median age 81 [interquartile range 75-85] years)...
April 30, 2024: ESC Heart Failure